Higher Gradient Whole-Body MRI Scanner Gets FDA Nod
At an amplitude of 200 mT/m and a slew rate of 200 T/m/s, the gradients for the FDA-cleared MAGNETOM Cima.X are reportedly the strongest for currently available whole-body MRI scanners.
Offering a robust gradient system and a variety of workflow enhancements, the MAGNETOM Cima.X 3T whole-body magnetic resonance imaging (MRI) scanner has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Siemens Healthineers, the manufacturer of the MAGNETOM Cima.X system, said the device features Gemini Gradients that have an amplitude of 200 millitesla per meter (mT/m) and a slew rate of 200 telsa per meter per second (T/m/s).
For imaging of patients with neurodegenerative diseases, the industry-leading gradient strength enhances the visibility of microstructures in the brain, according to Siemens Healthineers. The company noted that the MAGNETOM Cima.X system also features the artificial intelligence (AI)-powered Deep Resolve reconstruction technology, which can accelerate MRI brain scans by 70 percent.
The newly FDA-cleared, whole-body MAGNETOM Cima.X MRI system offers enhanced gradient strength that may facilitate improved visualization of brain microstructures as well as artificial intelligence (AI)-powered reconstruction technology that can accelerate MRI brain scans by 70 percent, according to Siemens Healthineers, the manufacturer of the system.
Another benefit of the whole-body MRI modality, according to Siemens Healthineers, is the capability to provide time-stamped physiological data through the system’s Physiologging feature, which enables clinicians to ascertain whether respiratory activity is compromising brain activity.
“With the FDA clearance of the MAGNETOM Cima.X, Siemens Healthineers proudly offers the scientific and medical communities a whole-body 3T MR scanner that can deliver penetrating new insights into oncologic, cardiac, and neurodegenerative disease,” noted Katie Grant, the vice president of magnetic resonance at Siemens Healthineers North America.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
